アブストラクト
| Title | 炎症性腸疾患のモニタリング - 非侵襲性バイオマーカー - |
|---|---|
| Subtitle | 今月のテーマ (総論) : 炎症性腸疾患におけるTreat to Targetのエビデンス |
| Authors | 小林拓1) |
| Authors (kana) | |
| Organization | 1)北里大学北里研究所病院炎症性腸疾患先進治療センター |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 3 |
| Page | 229-234 |
| Year/Month | 2021 / 3 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨: 炎症性腸疾患の診断や治療方針の決定において内視鏡はgold standardであるが, より非侵襲的なモニタリングの手法としてバイオマーカーが注目されている. 便中カルプロテクチンは, 炎症性腸疾患の診断, 内視鏡的重症度との相関, 治療効果判定, 再燃予測など, さまざまな場面においてその有用性が報告されている. 大腸癌スクリーニングに汎用されている便潜血反応検査も, 特に潰瘍性大腸炎の内視鏡的活動性をもよく反映することが示されているほか, 近年では血清leucine-rich glycoprotein (LRG), 尿中プロスタグランジンE主要代謝産物(PGE-MUM)などの有用性も報告されている. |
| Practice | 臨床医学：内科系 |
| Keywords | 便中バイオマーカー, 血清診断, 重症度診断, 潰瘍性大腸炎, クローン病 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kobayashi T, Siegmund B, Le Berre C, et al: Ulcerative colitis. Nat Rev Dis Primers 6;74:2020
- 2) Pevrin-Biroulet L, Sandborn W, Sands BE, et al: Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 110;1324-1338:2015
- 3) Roseth AG, Aadland E, Jahnsen J, et al: Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. Digestion 58;176-180:1997
- 4) Meucci G, D'Inca R, Maieron R, et al: Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis 42;191-195:2010
- 5) van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341;c3369:2010
残りの30件を表示する
- 6) 松岡克善,酒匂美奈子,高添正和,他:日本人における便中カルプロテクチンの有用性.医学と薬学 74;717-726:2017
- 7) D'Haens G, Ferrante M, Vermeire S, et al: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18;2218-2224:2012
- 8) Sipponen T, Karkkainen P, Savilahti E, et al: Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 28;1221-1229:2008
- 9) Zittan E, Kelly OB, Kirsch R, et al: Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis 22;623-630:2016
- 10) Lin JF, Chen JM, Zuo JH, et al: Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity. Inflamm Bowel Dis 20;1407-1415:2014
- 11) Roseth AG, Aadland E, Grzyb K: Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39;1017-1020:2004
- 12) Toyonaga T, Kobayashi T, Nakano M, et al: Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One 12;e185131:2017
- 13) Naganuma M, Kobayashi T, Nasuno M, et al: Significance of Conducting 2 Types of Fecal Tests in Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol 18;1102-1111.e5:2020
- 14) Gisbert JP, Bermejo F, Perez-Calle JL, et al: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15;1190-1198:2009
- 15) Molander P, Farkkila M, Ristimaki A, et al: Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 9;33-40:2015
- 16) Yamamoto T, Shimoyama T, Bamba T, et al: Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J Gastroenterol 110;881-887:2015
- 17) Boschetti G, Laidet M, Moussata D, et al: Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease. Am J Gastroenterol 110;865-872:2015
- 18) Yamamoto T, Shiraki M, Bamba T, et al: Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J 1;368-374:2013
- 19) Colombel JF, Panaccione R, Bossuyt P, et al: Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390;2779-2789:2018
- 20) D'Amico F, Nancey S, Danese S, et al: A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 15;152-161:2021
- 21) Sakata T, Niwa Y, Goto H, et al: Asymptomatic Inflammatory Bowel Disease With Special Reference to Ulcerative Colitis in Apparently Healthy Persons. Am J Gastroenterol 96;735-739:2001
- 22) Nakarai A, Kato J, Hiraoka S, et al: Evaluation of Mucosal Healing of Ulcerative Colitis by a Quantitative Fecal Immunochemical Test. Am J Gastroenterol 108;83-89:2013
- 23) Takashima S, Kato J, Hiraoka S, et al: Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. Am J Gastroenterol 110;873-880:2015
- 24) Beattie RM, Walker-Smith JA, Nlurch SH: Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73;354-355:1995
- 25) Shine B, Berghouse L, Jones JE, et al: C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 148;105-109:1985
- 26) Benitez JM, Meuwis MA, Reenaers C, et al: Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 62;1806-1816:2013
- 27) Denis MA, Reenaers C, Fontaine F, et al: Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 13;1100-1105:2007
- 28) Solem CA, Loftus EV Jr, Tremaine WJ, et al: Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11;707-712:2005
- 29) Louis E, Vermeire S, Rutgeerts P, et al: A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37;818-824:2002
- 30) Henriksen M, Jahnsen J, Lygren I, et al: C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 57;1518-1523:2008
- 31) Serada S, Fujimoto M, Terabe F, et al: Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18;2169-2179:2012
- 32) Shinzaki S, Matsuoka K, Iijima H, et al: Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 11;84-91:2017
- 33) Arai Y, Arihiro S, Matsuura T, et al: Prostaglandin E-Major Urinary Metabolite as a Reliable Surrogate Marker for Mucosal Inflammation in Ulcerative Colitis. Inflamm Bowel Dis 20;1208-1216:2014
- 34) Torres J, Petralia F, Sato T, et al: Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology 159;96-104:2020
- 35) D'Haens G, Kelly O, Battat R, et al: Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology 158;515-526.e10:2020
